The Polycomb group protein Bmi-1 is an essential regulator of cellular senescence and is believed to function largely through the direct repression of the Ink4a/Arf locus. However, concurrent deletion of Ink4a/Arf does not fully rescue the defects detected in Bmi-1 −/− mice, indicating that additional Bmi-1 targets remain to be identified. The expression of the chromatin-associated Sin3B protein is stimulated by oncogenic stress, and is required for oncogene-induced senescence. Here we demonstrate that oncogenic stress leads to the dissociation of Bmi-1 from the Sin3B locus, resulting in increased Sin3B expression and subsequent entry into cellular senescence. Furthermore, Sin3B is required for the senescent phenotype and elevated levels of reactive oxygen species elicited upon Bmi-1 depletion. Altogether, these results identify Sin3B as a novel direct target of Bmi-1, and establish Bmi-1-driven repression of Sin3B as an essential regulator of cellular senescence.
INTRODUCTION
Cellular senescence, an irreversible cell cycle arrest triggered by stress, is believed to prevent damaged or mutated cells from proliferating uncontrollably. 1, 2 Several studies have shown that the expression of senescence markers is associated with low proliferation in a wide variety of cancer preneoplastic lesions including lung adenoma, melanocytic naevi and PanIN. [3] [4] [5] For these reasons, cellular senescence has been long considered a tumor suppressor mechanism. 1, 6, 7 This hypothesis was further supported by the demonstration that genetic inactivation of proteins involved in the establishment of senescence promotes tumorigenesis in vivo. 8, 9 While the cellular factors that contribute to cellular senescence in response to oncogene activation remain for the most part unknown, numerous chromatin modifiers and chromatin-associated proteins have been shown to directly participate in the establishment and maintenance of the senescent phenotype. 10 Polycomb group proteins are evolutionary conserved proteins that regulate cell fate decisions, and mammalian Polycomb group proteins are components of complexes termed Polycomb repressive complexes (PRC1 and PRC2). 11, 12 PRC1 and PRC2 are targeted to specific loci and repress transcription through specific histone covalent modifications and chromatin compaction. 13 Bmi-1, a PRC1 component, was initially identified as a c-myc cooperating oncogene in the induction of B-cell lymphoma. 14, 15 Mice genetically inactivated for Bmi-1 exhibit numerous defects including growth retardation, hematological abnormalities, neurologic deficiencies and premature death. [16] [17] [18] At the cellular level, mouse embryonic fibroblasts (MEFs) deficient for Bmi-1 exhibit impaired S-phase progression and premature cellular senescence, correlating with the accumulation of the products of the Ink4a/Arf locus, p16
Ink4a and p19 Arf . 19 The cellular senescence phenotype elicited upon Bmi-1 depletion can be rescued by simultaneous inactivation of Ink4a/Arf in the mouse. 19 Later studies established that in proliferating cells, Bmi-1 binds throughout the Ink4a/Arf locus, directly repressing the expression of p16
Ink4a and p19
Arf .
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Bmi-1 −/− mice exhibit significant defects in various hematopoietic compartments including differentiation blocks in both Tand B-cell lineages. 18, 19, 21, 22 Concurrent deletion of Bmi-1 and Ink4a/Arf partially restores some of the hematopoietic abnormalities elicited in Bmi-1 −/− mice. However, Bmi-1 −/− Ink4a/Arf −/− mice still display numerous defects, including reduced numbers of nucleated thymocytes and splenocytes and a hypocellular bone marrow. 23, 24 These observations suggested that Bmi-1 has Ink4a/ Arf-independent functions, and therefore additional targets to be identified. Indeed, recent work has demonstrated that Bmi-1 regulates lymphoid lineage commitment through the Ink4a/Arfindependent repression of specific transcription factors. 22 In addition, loss of Bmi-1 leads to the detrimental accumulation of reactive oxygen species (ROS) levels in hematopoietic cells, regardless of the Ink4a/Arf status. 25 However, the molecular mechanism underlying the accumulation of ROS observed in Bmi-1 −/− hematopoietic cells remains to be identified. We have recently uncovered a central role for the histone deacetylase-associated Sin3B protein in cell cycle withdrawal. While Sin3B is dispensable for cell survival and proliferation in primary fibroblasts, it is required for entry into quiescence upon serum withdrawal, and for entry into cellular senescence triggered by serial passaging or oncogenic activation. 26, 27 Moreover, in cells rendered senescent in culture and in preneoplastic senescent lesions, the expression of Sin3B is transcriptionally upregulated. 27 The mechanism underlying this regulation of Sin3B is unknown. Here we identify Sin3B as a target of Bmi-1, and demonstrate that Sin3B is essential for the cellular phenotypes elicited upon Bmi-1 inactivation. using the indicated antibodies. Sin3B (Santa Cruz Biotechnology AK12), phosphorylated ERK (cell signaling 4377), H-Ras (Santa Cruz sc-520), alpha tubulin (Sigma T9026). Retroviral infections were performed as previously described. 27 (b) Relative Sin3B expression in wild-type MEFs infected with the indicated retroviruses as determined by qRT-PCR (n = 2) and reported to Beta-2-microglobulin (B2M). *Po 0.5, ***P o0.001 as determined by a Student's t-test. Data represent mean ± s.e.m. (c) Quantification of the proportion of SA-ßgal positive cells in MEFs infected with the indicated retroviruses (n = 2); at least 200 cells were counted per point. SA-ßGal staining was performed as previously described. 27 cultured in 6% O 2 , and infected no later than passage 2.
RESULTS AND DISCUSSION
expression. Of note, expression of oncogenic BRaf resulted in a significantly higher activation of Sin3B expression compared with that observed following oncogenic Ras expression, consistent with the recent demonstration that activation of the PI3K pathway antagonizes Ras signaling as it relates to senescence. 28 Importantly, activation of the MAPK pathway, but not activation of the RAL or the PI3K pathways, resulted in the initiation of the cellular senescence program, as demonstrated by increased SA-βGal positivity and decreased BrDU incorporation (Figures 1c and d) , indicating that increased expression of Sin3B correlates with the activation of an oncogene-induced senescence program. However, ectopic expression of oncogenic H-Ras or BRaf in immortalized MEFs that are unable to undergo senescence, also led to Sin3B upregulation (Figures 1e-g ), suggesting that Sin3B levels are modulated by oncogenic signals rather than cellular senescence per se.
The PRC1 component Bmi-1 represses Sin3B expression in proliferating cells The results presented above indicate that the Sin3B locus is maintained in a relative transcriptionally repressed state in proliferating cells but becomes activated upon oncogene activation. These observations are reminiscent of what has been reported for the Ink4a/Arf locus, which is transcriptionally repressed in proliferating cells but becomes actively transcribed following oncogene activation. This repression is mediated in primary fibroblasts by the polycomb group protein Bmi-1 along with other PRC1 components such as Cbx7 and Cbx8, 20, [29] [30] [31] leading us to investigate whether Bmi-1 similarly regulates Sin3B expression. Indeed, ectopic expression of Bmi-1 strongly decreased both Sin3B transcript and protein levels in primary MEFs (Figures 2a and b) . Importantly, Bmi-1-driven repression of Bmi Figure 1A) . Conversely, short-hairpin RNA (shRNA)-mediated knockdown of Bmi-1 resulted in a significant increase of Sin3B messenger RNA and protein levels (Figures 2c and d) . As Bmi-1 has been reported to prevent the occurrence of senescence, it remained possible that the Bmi-1-dependent modulation of Sin3B was merely due to senescence. We believe this to be unlikely, as Bmi-1 overexpression resulted in the downregulation of Sin3B levels in immortalized MEFs (NIH 3T3), while Bmi-1 knockdown led to an increase in Sin3B transcript abundance in these cells ( Supplementary Figures 2A and B) . These results indicate that Sin3B is a bona fide downstream target of the Polycomb protein Bmi-1.
To explore the possibility that the Sin3B locus is a direct target of Bmi-1, we took advantage of the tamoxifen-inducible BRaf V600E − ERT1 chimeric protein. 32 In early passage MEFs expressing BRaf V600E − ERT1 , tamoxifen administration resulted in activation of the BRaf pathway, as evidenced by the accumulation of phosphorylated ERK1/2 (Figure 2e ). More specifically, induction of the BRaf pathway led to the transcriptional activation of Sin3B, p16 Ink4a , and p19 Arf (Figure 2e and Supplementary Figure 3) . Tamoxifen addition to wild-type MEFs did not alter Sin3B transcript or protein levels, demonstrating that the changes in Sin3B levels were due to BRaf activation (Supplementary Figures  4A and B) . Interestingly, a time course study indicated that Sin3B upregulation is an early event following BRaf V600E activation, and precedes the induction of established markers of senescence, including GLB1 and IL-6 [33] [34] [35] (Supplementary Figure 3) . This observation is consistent with Sin3B upregulation being driven by oncogenic activation rather than by senescence itself. To examine the molecular mechanisms underlying Bmi-1 modulation of Sin3B expression, we performed Chromatin ImmunoPrecipitation experiments on primary MEFs, before or after BRaf V600E activation. Prior to BRaf V600E activation, Bmi-1 was found weakly but reproducibly enriched at the Sin3B transcription start site, compared with a control locus (gapdh) or a non relevant serum (Figure 2f ). Following BRaf V600E activation, Bmi-1 was released Table 1. (a-g) Cells were harvested 6 days following selection.
from the Sin3B locus, coinciding with an increase in Sin3B transcription. Together, these experiments suggest that the repressor Bmi-1 is tethered to the Sin3B locus in proliferating cells, and released upon oncogenic stress, coinciding with its transcription.
Sin3B null cells are refractory to Bmi-1 knockdown-induced cellular senescence Bmi-1 depletion in primary fibroblasts leads to cellular senescence. 19 Based on the demonstration that Sin3B is a direct target of Bmi-1 repression, and that Sin3B promotes replicative and oncogene-induced senescence, 27 we investigated whether Sin3B upregulation contributed to the cellular senescence elicited upon a decrease in Bmi-1 levels. shRNA-mediated knockdown of Bmi-1 in early passage Sin3B +/+ and Sin3B − / − MEFs resulted in a 70% reduction in Bmi-1 transcript levels. As expected, Bmi-1 depletion correlated with an increase in Sin3B messenger RNA and protein levels only in wild-type MEFs, while an increase in p16 Ink4a and p19
Arf messenger RNA abundance was detected upon Bmi-1 knockdown in both Sin3B +/+ and Sin3B − / − MEFs (Figures 3a and  b) . In agreement with previous reports, decreasing Bmi-1 levels in wild-type MEFs resulted in a significant reduction in BrDU incorporation and an increase in SA-βGal positivity, indicative of premature entry into senescence (Figures 3c and d) . Strikingly, genetic inactivation of Sin3B fully rescued the cell cycle withdrawal and premature entry into senescence elicited by Bmi-1 knockdown (Figures 3c and d) . Sin3B inactivation prevented the entry into senescence elicited by Bmi-1 depletion despite the upregulation of p16
Arf , indicating that the products of the Ink4a/Arf locus may be unable to modulate cell cycle exit in the absence of Sin3B. Indeed, similar to what was observed upon Bmi-1 knockdown, Sin3B was required for cell cycle withdrawal and entry into cellular senescence induced by p16
Arf overexpression (Figures 3e-g ).
Sin3B is required for the elevated ROS levels in Bmi-1 depleted cells Recent work has demonstrated that Bmi-1 prevents the detrimental accumulation of ROS in both neurons and hematopoietic cells. 25, 36 Increases in ROS are a primary cause of cellular senescence in MEFs as culturing MEFs in low oxygen conditions prevents entry into cellular senescence. 37 Furthermore, ROS accumulation contributes to the senescence phenotype upon oncogenic stimuli. 38, 39 We have previously demonstrated that Sin3B directly and specifically represses the transcription of several nuclear-encoded mitochondrial genes in differentiated myotubes. 40 Since Sin3B −/− MEFs are resistant to premature senescence elicited by oncogene signaling and Bmi-1 depletion, we hypothesized that Sin3B levels may modulate ROS accumulation downstream of Bmi-1.
To separate the accumulation of ROS resulting from entry into senescence from that caused specifically by Bmi-1 depletion, we generated immortalized Sin3B +/+ and Sin3B −/− murine fibroblasts using a 3T3 protocol (Figure 4a ). These cells are unable to undergo cellular senescence upon Bmi-1 depletion (data not shown). As previously reported in multiple cell types, 25, 36 lowering Bmi-1 levels using two independent shRNAs increased the levels of intracellular ROS in Sin3B +/+ 3T3s. Strikingly, Sin3B −/− 3T3s fail to exhibit increased ROS accumulation upon Bmi-1 depletion (Figures 4b-d) .
In summary, these results demonstrate that Sin3B is an essential regulator of the cell cycle withdrawal and the cellular consequences elicited upon Bmi-1 depletion. It could be argued that Sin3B −/− MEFs require additional mutations to proliferate in culture, which would confound our conclusion that Sin3B is required for entry into cellular senescence upon Bmi-1 depletion. However, our results do not support this interpretation. First, the proportion of mid-gestation Sin3B −/− embryos obtained from Sin3B heterozygous crosses is 25%, indicating that no additional stochastic mutation is required for Sin3B −/− embryonic cells to grow in vivo. 26 Second, Sin3B −/− MEFs proliferate similarly to wild-type MEFs at early passages and do not undergo proliferative crisis for at least twenty-six passages. 26, 27 Therefore, the clonal selection of a stochastic mutation is not occurring in Sin3B −/− MEFs, in contrast to what has been observed for other knockout MEF lines (for example, Zhang et al. 41 and Wang et al. 42 ). Along with the fact that our experiments were performed in primary MEFs at early passage, our data support the conclusion that Sin3B inactivation is sufficient to suppress the cellular senescent phenotype elicited by Bmi-1 depletion.
Our observations also indicate that oncogenic stress leads to the dissociation of the Bmi-1 protein from the Sin3B locus. Interestingly, it has been recently demonstrated that oncogenic activation promotes Bmi-1 phosphorylation, resulting in its dissociation from the chromatin fiber, thus providing a potential molecular basis for Bmi-1's release from the Sin3B locus upon oncogene activation. 43, 44 In addition, our results indicate that ROS accumulation upon Bmi-1 depletion depends on the presence of Sin3B. How Sin3B prevents the accumulation of ROS is not entirely clear at this point. As we have recently demonstrated that Sin3B directly and specifically represses the transcription of several nuclear-encoded mitochondrial genes in differentiated myotubes, 40 it is tempting to speculate that Sin3B levels and activities may alter mitochondrial metabolism, ultimately regulating ROS production. These observations indicate that Sin3B serves as the elusive molecular link between Bmi-1 and mitochondrial function. Finally, given the wellestablished pro-oncogenic function of Bmi-1 in human cancers, it will be interesting to assess the contribution of Sin3B expression in preventing cellular transformation. Since Sin3B deletion, unlike Ink4a/Arf deletion, does not sensitize to oncogenic transformation, 27 it may therefore represent an ideal therapeutic target for mitigating the deleterious effects of a wide variety of stress, including those triggered by loss of Bmi-1 expression. Consistent with this hypothesis, we have recently demonstrated that Sin3B inactivation delays oncogenic Ras-driven tumorigenesis in a mouse model of pancreatic cancer. 45 Based on the results presented here, we speculate that this property may be linked to the ability of Sin3B to modulate ROS levels in response to stress, a hypothesis that remains to be investigated.
